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 Abbreviations 
BAFF  B cell activating factor 
CADI  chronic allograft damage index 
CAR  chimeric antigen receptor 
cf  cell free 
GWAS genome wide association studies 
iPSC  induced pluripotent stem cells 
IRI  ischemia reperfusion injury 
MSC  mesenchymal stem cells 
NK  natural killer 
PCR  polymerase chain reaction 
TCR  T cell receptor 
Tfh  follicular T helper 
Treg   regulatory T cell 
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 Abstract  
Over 3000 delegates attended the 26st International Congress of the Transplantation Society in 
Hong Kong, which marked the 50
th
 anniversary of the society. In his presidential address, 
Professor Phil O’Connell from the Westmead Hospital in Sydney, Australia, commented that a 
major challenge for the future is improving long-term outcomes after solid organ transplantation. 
He highlighted that 40% of transplanted organs are lost within 10 years, and that a high 
proportion of patients suffer from immunosuppression-related side effects. These two issues are 
the key drivers for basic scientists in the field of transplantation. A deeper understanding of the 
biological mechanisms involved, and more accurate identification of patients at risk for poor 
outcomes or drug-related adverse effects, will ultimately help to address these problems and 
improve graft survival rates and patients' quality of life. The research was more diverse than ever 
before, reflecting the variety and complexity of the many processes which underlie outcomes 
after transplantation, and the need to broaden our thinking when seeking solutions to the wide-
ranging complications which face the transplant team. This article explores the latest 
developments in basic science presented at the Congress which may offer new insights and 
solutions to the current challenges in organ transplantation. With so many interesting papers 
presented, it is impossible to discuss everything, but some key areas are considered.  
  AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 Overcoming barriers in xenotransplantation 
In the plenary session 'Transformational Sciences in Transplantation?' Professor Joseph Tector 
from the University of Alabama in the United States gave a presentation entitled 'CRIPR/CAS9 – 
The promise of gene editing technologies in transplantation'. According to Science, this 
technology was the major breakthrough of 2015,
1
 and is expected to have the same impact as the 
Nobel prize-winning discovery of polymerase chain reaction (PCR) in the late 1980s.
2
 Parts of 
the CRISPR/CAS9 system cannot easily be translated into simple terms,
1
 but the crucial point is 
that it is a gene editing system which can knock out a gene in cells, with many potential 
applications. The system consists of a short segment of RNA that is attached to an enzyme. The 
RNA is preprogrammed to locate a unique short sequence of DNA and slice it out of the genome. 
It acts rapidly and is relatively precise. This technology opens up the possibility of conveniently 
knocking out genes involved in disease processes – and also genes that are a barrier to 
xenotransplantation. It has already found its way to the clinic, with one of the first registered 
clinical studies being undertaken by scientists at the West China Hospital in Chengdu, China, 
who are using the CRISPR/CAS9 system to knock out the gene encoding for immune checkpoint 
receptor PD-1. Activation of this receptor normally acts as a 'brake' on the ability of T cells to 
launch an immune response.
3
 The gene-edited T cells, without PD-1, will then be expanded in 
the laboratory and re-introduced into the patient’s bloodstream where it is hoped they will 
migrate into cancers to stop their growth or even decrease the tumor mass.
3
  CRISPR/CAS9 
could potentially revolutionize transplantation and transplantation immunology. In 
xenotransplantation, for example, it allows endogenous porcine retroviruses to be inactivated, 
avoiding the risk for retrovirus infection of human cells.
4,5
 Yang and colleagues have shown that  
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 CRISPR/CAS9 can be used to inactivate 62 active virus sequences embedded in the pig genome, 
resulting in a dramatic reduction of virus production.
5
 This technology can also be used to 
genetically modify pigs to suppress the human anti-pig immune reaction, as described by Tector 
and his team.
6
   
 
Advances in immune monitoring 
There is a growing movement towards standardization of immune monitoring and biomarker 
studies, including standardized blood collection procedures and techniques such as flow 
cytometry and Elispot.
7
 This is vital to avoid the problems associated with use of nonvalidated 
biomarkers, which are likely to have contributed to nonreproducible laboratory data over the past 
10–20 years. Even small variations in cell isolation procedures, incubation times, or choice of 
reagents or equipment influence measurement outcomes, all of which can be minimized by using 
standardized procedures.  
 
With this in mind, the talk by Matthew Albert from Genentech in the United States on next-
generation immune monitoring provided a helpful update on new directions in this field. He 
emphasized that large-scale human immune profiling can be successful if an integrated omics 
approach is applied, with genome-wide association studies (GWAS) being supported by immune 
cell function studies. Since cell function in the adaptive immune system is heavily influenced by 
environmental factors, standardization of blood collection and culture procedures is essential in 
order to avoid wide fluctuations in T and B cell function induced by irrelevant factors. Albert 
stressed that standardized approaches in biomarker research are also needed during drug  
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 development, enabling transcriptional profiling to elucidate complex-induced immune 
responses.
8
   
 
There is a clear imperative to improve biomarker research. The technical developments 
described by Matthew Albert, and by the virtual Global Transplantation Laboratory group, will 
enable identification of patients at risk for graft loss, and offer an understanding of the 
underlying immune processes. This will provide a deeper knowledge about the mode of action of 
immunosuppressive drugs, the main focus of research. Results from these biomarker studies will 
be instrumental in developing immunosuppressive therapies tailored to the individual patient. 
 
A glimpse of how future biomarker studies in transplantation could be designed, and the 
implications of their results, is given by the GoCAR study undertaken by O’Connell and 
collegues.
9
 The authors analyzed 159 protocol renal biopsies using the affymetrix gene 
expression array, and divided the cohort into a discovery set and a validation set. The results 
demonstrated that genes associated with development of fibrosis are already highly expressed 
three months after transplantation in patients with a high biopsy chronic allograft damage index 
(CADI) score at 12 months. This was associated with early graft failure and was predictive for 
graft loss. Data presented by Valeria Mas from the University of Virginia in the United States on 
the genomics of allograft fibrosis and rejection
10 
are in line with these results. Altogether, these 
data point to an ongoing cycle of subclinical inflammation and injury that leads to fibrosis, loss 
of function and graft failure. In addition, these studies demonstrate an urgent need for specialized  
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 immunosuppression targeting fibrotic molecules and pathways, an important challenge for the 
coming years. 
 
Ischemia reperfusion injury and tissue repair 
A leading topic at the Congress was the prevention and treatment of ischemia reperfusion injury 
(IRI). Several papers were presented on the role of the immune system in IRI. One concerned the 
study by Zarrinpar and colleagues from the University of California in the United States, who 
demonstrated that the expression of innate and adaptive cytokines correlate with the degree of 
IRI.
11
 The important point about this study is that it was performed in a large cohort of liver 
transplant patients, thereby confirming findings of previous animal studies.   
 
Other insights have led to the development of innovative approaches and agents for treating IRI 
via nanoparticles, as presented by Stead et al
12
 from the Royal Adelaide Hospital in Australia, 
and by follistatin, as shown in a study by Cowan and colleagues from St Vincent's Hospital in 
Melbourne, Australia.
13
 For example, follistatin binds and inhibits the activity of activins, 
members of the TFG-ß superfamily and key drivers of fibrosis. In a mouse model of IRI, 
intramuscular injection of a recombinant adeno-associated viral vector carrying the follistatin 
gene resulted in sustained elevation of circulating follistatin levels and was associated with 
reduced renal expression of pro-fibrotic TFG-ß, and type I and IV collagen, with improved renal 
function and amelioration of IRI-induced fibrosis. 
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 Many presentations were given by scientists from around the world about the most appropriate 
preservation system for donor organs, according to their quality, to achieve optimal outcomes: 
hypothermic or normothermic, static or perfused, continuous or final (either exclusively or 
possibly in combination).
14
 These subjects were discussed in a commentary by Hunter and 
Ploeg
14
 from the University of Oxford, United Kingdom, regarding a paper by Kaths and 
colleagues from the University of Toronto and from the Johannes Gutenberg University in 
Mainz, Germany
15
 who reported that eight hours of continuous normothermic ex vivo kidney 
perfusion is a safe preservation technique that does not cause graft injury. 
 
The subject of repairing tissue in damaged donor organs, based on the application of 
bioengineering skills to organ transplantation, was presented by Orlando from the Wake Forrest 
School of Medicine in the United States and by Hoogduijn from the Erasmus Medical Center in 
Rotterdam, The Netherlands. The talk by Guiseppe Orlando about printing organs was truly 
spectacular and showed that bioprinting living tissues is close to becoming reality, and is no 
longer science fiction. His presentation highlighted the possibilities for bioprinting and explored 
how it might be used to address the needs in organ transplantation by providing organs on 
demand without the need for immunosuppression, and potentially helping to repair injured 
tissues
16
. Of course, bioprinting still has its limitations but progress is being made in finding 
solutions for questions such as the choice of cell types and biomaterials, and relating to 
vascularization and innervation of the printed tissue constructs to achieve normal tissue function. 
The progress made over the last couple of years is most encouraging. Hoogduijn presented data 
on kidney regeneration through delivery of human mesenchymal stem cells (MSC), which are  
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 known for their immunomodulatory properties.
17-19
 Another solution to organ repair might be 
found in growing organs from human induced pluripotent stem cells (iPSC). Hoogduijn has used 
the protocol published by Takasato in Nature in 2015
20
 using these iPSCs to grow kidney cells.
 
 
Pilot experiments have shown remarkably complex structure formation in human iPSC-derived 
organoids after 18 days of differentiation. Staining on sectioned kidney organoids showed the 
presence of cells organized in tubule-like structures with an open lumen. In addition, q-PCR of 
iPSC genes demonstrated reduced expression, whereas expression of early kidney genes was 
strongly induced, confirming differentiation towards kidney-like cells.  
 
Over the last few years, impressive progress has been made in the generation of insulin-
producing cells. Studies by Zavazava from the University of Iowa in the United States showed 
that differentiated human iPSCs secrete insulin after transplantation of the organoid under the 
kidney capsules of diabetic immune-deficient mice. Serum glucose levels gradually declined to 
normal or near-normal levels over time. Furthermore, the pancreatic organoids showed 
neovascularization and stained positive for insulin and glucagon.
21
 Others, such as scientists 
working in Doug Melton's team, published data showing that stem cell-derived ß-cells can be 
generated directly from human iPSCs and that these cells exhibit similar function  to primary 
human ß-cells in vitro and in vivo posttransplantation.
22
 These promising data show that a 
pancreatic organ can be created by human pluripotent stem cells and that cell treatment is a 
promising new option for the management of type 1 diabetes.  
 
 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 The adaptive immune system: Regulatory T cells, tolerance and immune monitoring 
For many years, regulatory T cell (Treg) therapy has attracted intense interest. Although having 
been a familiar topic for some time, optimized in vitro expansion protocols for regulatory T cell 
(Treg) therapy have only recently been developed.
23-25
 Paul Harden from the University of Oxford 
in the United Kingdom presented data on 11 patients treated with polyclonally-expanded Treg 
which were infused shortly after kidney transplantation.
26
 No adverse events related to the 
infusion were observed and patients showed excellent kidney graft function. This study 
demonstrated elegantly that Treg therapy is feasible and may be efficacious. However, the 
transient risk of generalized immunosuppression by these nonspecific Treg cannot be ignored, 
since only a low percentage of the polyclonally-expanded Treg are alloantigen specific. For this 
reason, and because animal studies have shown that antigen-specific Treg are more potent, it may 
be preferable to treat patients with antigen-specific Treg. Megan Levings from the University of 
British Colombia in Canada spoke about how the hurdles of expanding antigen-specific Treg can 
be overcome. First, alloantigen-specific Treg can be expanded, but this is a slow process and 
requires access to donor antigen. Second, a transgenic T cell receptor (TCR) approach can be 
followed although this is quite time consuming, Third, the chimeric antigen receptor (CAR) 
approach which has been developed in the field of oncology can be utilized. In her presentation, 
Levings demonstrated that these CAR Treg are potent suppressors of alloreactivity. It is 
hypothesized that patients who are HLA-A2 negative and receive a HAA-A2 positive kidney 
will receive Treg which also recognize HLA A2 and control the anti-donor response to protect the 
transplanted organ.
27
 In a xenograft versus host model, these CAR Treg effectively protected the 
animals from disease development. Thus, CAR technology means it is now possible to generate  
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 potent, functional, and stable alloantigen-specific human Treg that will markedly enhance their 
therapeutic potential in transplantation.
27 
 
New mechanistic data have been presented by Bézie from INSERM at Nantes in France and by 
Bromberg from the University of Maryland in the United States. These teams have explored the 
role of cytokines in Treg function and the impact of lymph node basement membrane proteins on 
Treg proliferation and polarization. Bézie observed that IL-34, a cytokine which signals via the 
M-CSF receptor and promotes monocyte survival, also promotes Treg function.
28,29
 In their 
studies, polyclonally-expanded Treg were more potent suppressors when grown in the presence of 
IL-34.
29
 Bromberg presented intriguing data indicating that that proteins called laminins, which 
contribute to the structure of extracellular matrix, also influence the action of T cells. In a pro-
Treg environment, laminin 511 inhibited Treg induction, an effect for which alpha 6 integrin is 
essential, while in an IL-17 milieu laminin 511 favored Th17 induction via α dystroglycan. 
These studies show that lymph node laminins act as molecular switches for tolerance and 
immunity by directly influencing T cell proliferation and polarization.
30
  
 
In addition to treating patients with cells to control the anti-donor response, or even induce 
tolerance, there is also great interest in tools that can identify whether patients have developed 
tolerance or have an immunologic quiescent profile so that immunosuppression can be tapered 
accordingly. A group working with Megan Sykes at the Columbia University Medical Center in 
the United Stated has used the classic mixed lymphocyte reaction, combined with T cell receptor 
sequencing, to measure the anti-donor T cell receptor repertoire before transplantation. This is  
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 then compared to the repertoire after transplantation to identify and track alloreactive clones. 
Their first data showed that tolerant kidney transplant patients show significant deletion of T cell 
clones.
31
 Future studies are needed to confirm if this assay can indeed be used to detect patients 
who have become tolerant. 
 
 
B cells and the humoral anti-donor response 
In an early morning session on 'B cells and antibodies', Dr Di Yu from Monash University in 
Australia presented data on the mechanisms and cells required to produce high-affinity 
antibodies in a talk entitled 'What are the key signals for B cell activation?. Yu explained that 
follicular T helper (Tfh) cells are essential for the anti-donor B cell response. These Tfh cells 
reside in the germinal centers of lymph nodes and spleen, where they contribute to antigen-
activated B cell activity via co-stimulation signals such as CD40L, ICOS and PD-1, and by 
production of IL-21.
32
 Studies by Kitty de Leur and colleagues have demonstrated that lymphoid 
follicles and Tfh cells are present in the transplanted kidneys of immunosuppressed patients.
33,34
 
In chronic antibody-mediated rejection, one of the main causes of late organ failure, serum donor 
specific antibodies (DSA) are an important and well-established diagnostic biomarker. At the 
meeting, several talks described the latest developments for improving the prognostic value of 
assays which detect and quantify DSA and anti-HLA antibodies, particularly in patients with a 
poor prognosis due to the presence of complement-fixing DSA.
35
 Lionel Rostaing from Grenoble 
in France presented data showing that complement activation might depend on the concentration 
of DSA.
36
 Dr Cai from the Terasaki Foundation laboratory in Los Angeles discussed how C1q- 
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 fixing antibodies against denatured HLA and MICA antigens are associated with antibody-
mediated rejection after kidney transplantation.
37
 
 
Anti-donor antibodies are mostly of the IgG subtype which binds to both HLA and non-HLA 
antigens expressed by the grafted organ, and are responsible for the pathology which reduces 
graft survival. IgG antibodies activate complement and can also engage with the surface Fc 
gamma receptors that are expressed on macrophages, dendritic cells, neutrophils and natural 
killer (NK) cells. Dr. Menna Clatworthy from the University of Cambridge in the United 
Kingdom spoke about the available immunosuppressive agents which specifically target B cells 
and antibody-producing cells.
38
 She proposed a concept whereby nonsensitized patients should 
receive treatment that prevents naïve B cell activation, while in patients who have developed de 
novo antibodies or have an acute B cell-mediated rejection episode the plasma cell germinal 
center reaction should be prevented. In sensitized DSA-positive patients, memory B cells and 
long-lived plasma cells should be targeted. Thus, instead of a 'one-size-fits-all' strategy for global 
B cell depletion in patients with antibody-mediated rejection, more targeted therapy should be 
applied to achieve optimal efficacy with minimal safety concerns. Unfortunately, few studies 
reporting the outcomes of randomized controlled trials targeting B cells and/or plasma cells were 
presented at the meeting. Such studies should be initiated to establish their efficacy and safety 
profile in transplant patients. A first indication may come from a Phase 2 safety study targeting 
the B cell activating factor (BAFF) molecule belimumab in kidney transplant patients 
(www.clinicaltrials.gov/ NCT 1536379). 
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 How will transplantation change over the next five years? 
At the end of the 5-day meeting is was clear that there are no simple answers to improving long-
term graft and patient outcomes after solid organ transplantation. This report touches on only a 
few of the many highlights of the Congress. No less important are recent insights into the role of 
microbiota on the immune system, monocytes and dendritic cells, NK cells and trained 
immunity, memory T cells, T cell exhaustion, co-stimulation and co-inhibition, and biomarkers 
such as cell free (cf) donor DNA.  
 
Over the years we have learned that complications affecting outcomes after transplantation have 
multiple causes, involving immunological, pro-fibrotic and inflammatory processes as well as 
the consequences of lifelong treatment with toxic immunosuppressive drugs. The transplant 
community can collaborate, sharing protocols, data and patient materials to speed up the 
discovery process. Within five years, it is quite feasible that we will 1) work with standardized 
reagents, equipment and techniques in the laboratory to increase the quality of results; 2) have a 
set of reliable biomarkers to predict late graft failure; 3) treat type I diabetic patients with 
embryonic stem cells(ES) and or iPS (induced pluripotent stem cells) generated ß-cells; 4) apply 
cell therapy with Treg on a much larger scale and 5) have developed anti-B cell therapies to 
prevent and treat antibody-mediated rejection implemented in the clinic. These advances 
represent key steps to further improving long-term graft and patient outcomes after 
transplantation. 
 
  
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 References 
1. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with 
CRISPR-Cas9. Science. 2014;346:1258096.   
2. Mullis KB, Ferré F, Gibbs RA [eds]. The Polymerase Chain Reaction. Birkhäuser Press, 
Boston, USA; 1994 pp. 1–458. ISBN 0-8176-3750-8  
3. Cyranoski D. Chinese scientists to pioneer the first human CRISPR trial. Nature News 
(www.nature.com/news) published July 21
st
, 2016. 
4. Salomon DR. Commentary in A CRISPR Way to Block PERVs--Engineering Organs for 
Transplantation. N Engl J Med. 2016;374:1089–1091. 
5. Yang L, Güell M, Niu D, et al. Genome-wide inactivation of porcine endogenous 
retroviruses (PERVs). Science. 2015;350:1101–1104.  
6. Butler JR, Martens GR, Estrada JL, et al. Silencing porcine genes significantly reduces 
human-anti-pig cytotoxicity profiles: an alternative to direct complement regulation. 
Transgenic Res. 2016 Apr 21 [Epub ahead of print] 
7. Higdon LE, Lee K, Tang Q, Maltzman J. Virtual global transplant laboratory standard 
operating procedures for blood collection, PBMC isolation and storage. Transplantation 
Direct. 2016;2:e101.  
8. Urrutia A, Duffy D, Rouilly V, et al; Milieu Intérieur Consortium. Standardized whole-blood 
transcriptional profiling enables the deconvolution of complex induced immune responses. 
Cell Rep. 2016;16:2777–2291. 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
9. O'Connell PJ, Zhang W, Menon MC, et al. Biopsy transcriptome expression profiling to 
identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet. 
2016;388:983–993.  
10. Maluf DG, Mueller TF, Mas VR. Hidden inflammatory molecular signatures in graft kidney 
biopsies: silent markers of graft fate?  Am J Transplant. 2016;16:1947–1948. 
11. Zarrinpar A, Sosa R, Rao P, et al. Evolution of innate and adaptive cytokine responses in 
ischemia reperfusion injury in orthotopic liver transplantation. Transplantation 
2016;100(7S):S123. 
12. Stead S,  McInnes S, Kireta S, et al. Dendritic cell phenotype and function modification with 
targeted porous silicon nanoparticles. Transplantation. 2016;100(7S):S234.  
13. Fang D, Lu B, Hayward S, Kretser de D, Cowan P, Dwyer K. Follistatin modulates ischemia-
reperfusion-induced renal fibrosis in mice. Transplantation. 2016;100(7S):S234.  
14. Hunter JP, Ploeg RJ. An exciting new era in donor organ preservation and transplantation: 
assess, condition, and repair! Transplantation. 2016;100:1801–1802. 
15. Kaths JM, Echeverri J, Goldaracena N, et al. Eight hour continuous normothermic ex vivo 
kidney perfusion is a safe preservation technique for kidney transplantation: a new 
opportunity for the storage, assessment and repair of kidney grafts. Transplantation. 
2016;100:1862–1870. 
16. Kang HW, Lee SJ, Ko IK, Kengla C, Yoo JJ, Atala A. A 3D bioprinting system to produce 
human-scale tissue constructs with structural integrity. Nat Biotechnol. 2016;34:312–319.  
17. Hoogduijn MJ, Betjes MG, Baan CC. Mesenchymal stromal cells for organ transplantation: 
different sources and unique characteristics? Curr Opin Organ Transplant. 2014;19:41–46. 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
18. Franquesa M, Hoogduijn MJ, Reinders ME, et al; MiSOT Study Group. Mesenchymal Stem 
Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first 
clinical trials. Transplantation. 2013;96:234–238. 
19. Neofytou E, Deuse T, Beygui RE, Schrepfer S. Mesenchymal stromal cell therapy: different 
sources exhibit different immunobiological properties. Transplantation. 2015;99:1113–1118. 
20. Takasato M, Er PX, Chiu HS, et al. Kidney organoids from human iPS cells contain multiple 
lineages and model human nephrogenesis. Nature. 2015;526:564–568.  
21. Raikwar SP, Kim EM, Sivitz WI, Allamargot C, Thedens DR, Zavazava N. Human iPS cell-
derived insulin producing cells form vascularized organoids under the kidney capsules of 
diabetic mice. PLoS One. 2015;10:e0116582] 
22. Vegas AJ, Veiseh O, Gürtler M, et al. Long-term glycemic control using polymer-
encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med. 
2016;22:306–311.  
23. Petrelli A, Tresoldi E, Mfarrej BG, et al. Generation of donor-specific t regulatory type 1 
cells from patients on dialysis for cell therapy after kidney transplantation. Transplantation. 
2015;99:1582–1589. 
24. Baan CC. Highlights in basic sciences: On our way to solutions. Transplantation. 
2015;99274–275. 
25. van der Net JB, Bushell A, Wood KJ, Harden PN. Regulatory T cells: first steps of clinical 
application in solid organ transplantation. Transpl Int. 2016;29:3–11.  
26. Bushell AR, van der Net J, Game DS, et al. The UK ONE Study trial: safety and feasibility 
of Treg therapy in renal transplantation. Transplantation 2016;100(7S):S120. 
CC
EP
TE
D
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
27. MacDonald KG, Hoeppli RE, Huang Q, et al. Alloantigen-specific regulatory T cells 
generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413–1424.  
28. Foucher ED, Blanchard S, Preisser L, et al. IL-34 induces the differentiation of human 
monocytes into immunosuppressive macrophages. Antagonistic effects of GM-CSF and 
IFNγ. Plos One. 2013;8:e56045. 
29. Bézie S, Picarda E, Ossart J, et al. IL-34 is a Treg-specific cytokine and mediates transplant 
tolerance J Clin Invest. 2015;125:3952–3964.  
30. Warren KJ, Iwami D, Harris DG, Bromberg JS, Burrell BE. Laminins affect T cell 
trafficking and allograft fate. J Clin Invest. 2014;124:2204–2218. 
31. DeWolf S, Shen Y, Sykes M. A new window into the human alloresponse. Transplantation. 
2016;100:1639–1649. 
32. Walters GD, Vinuesa CG. T follicular helper cells in transplantation. Transplantation. 
2016;100:1650–1655. 
33. Leur de K, de Graav de GN, Boer K, et al.  Ectopic lymphoid follicles are present in type I T-
cell mediated kidney transplant rejection Transplantation. 2016;100(7S):S454. 
34. de Graav GN, Dieterich M, Hesselink DA, et al. Follicular T helper cells and humoral 
reactivity in kidney transplant patients. Clin Exp Immunol. 2015;180(2):329-40. 
35. Yell M, Muth BL, Kaufman DB, Djamali A, Ellis TM. C1q binding activity of de novo 
donor-specific HLA antibodies in renal transplant recipients with and without antibody-
mediated rejection. Transplantation. 2015;99:1151–1155. 
36. Malvezzi P, Villemaire M, Jouve T, Legall A, Masson D, Rostaing L. Correlation between 
C3d-fixing donor specific HLA antibody and luminex MFI. Transplantation. 
2016;100(7S):S26.  
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
37. Cai J, Huang W, Rebellato LM, et al. C1q-fixing antibodies against denatured HLA and 
MICA antigens are associated with antibody mediated rejection. Transplantation. 
2016;100(7S):S27. 
38. Inaba A, Clatworthy MR. Novel immunotherapeutic strategies to target alloantibody-
producing B and plasma cells in transplantation Curr Opin Organ Transplant. 2016;21:419–
426.  
 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
